Email
IZ Express #1,773: ACIP influenza recommendations, 2024–25 Novavax COVID-19 vaccine, Ask the Experts: RSV, and more
| From | Immunize.org <[email protected]> |
| Subject | IZ Express #1,773: ACIP influenza recommendations, 2024–25 Novavax COVID-19 vaccine, Ask the Experts: RSV, and more |
| Date | September 4, 2024 10:01 AM |
Links have been removed from this email. Learn more in the FAQ.
Links have been removed from this email. Learn more in the FAQ.
[link removed] [link removed] [link removed] [link removed] [link removed]
Email not displaying correctly? View it in your browser. ([link removed])
[link removed]
Issue 1,773: September 4, 2024
Top Stories
* “Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2024–25 Influenza Season” published in MMWR (#IZX1)
* FDA authorizes updated protein-based Novavax COVID-19 vaccine for people age 12 years and older to better protect against currently circulating variants (#IZX2)
* Immunize.org updates “Ask the Experts: RSV (Respiratory Syncytial Virus)” web section for the 2024–25 season (#IZX3)
* Immunize.org updates “Vaccinations for Adults: You’re Never Too Old to Get Vaccinated!” handout with current pneumococcal and RSV recommendations (#IZX4)
* Immunize.org updates the Spanish translations of 2024–25 screening checklists for contraindications to injectable and nasal influenza vaccines (#IZX5)
* CDC’s Bridge Access Program to provide free COVID-19 vaccines to uninsured or underinsured adults ended (#IZX6)
* Watch and share the latest installment in Immunize.org’s Orientation Video Series: Introducing Immunize.org (mobile view) to see how our new mobile site looks on your smartphone! (#IZX7)
* IZ Express keeps 54,000+ readers up to date on what’s new in vaccines each week; invite your colleagues to subscribe (#IZX8)
* Journalists interview Immunize.org experts (#IZX9)
* Vaccines in the news (#IZX10)
Immunize.org Website and Clinical Resources
* Spotlight on the website: Ask the Experts video questions and answers (#IZX11)
* Recap: Immunize.org updates “Ask the Experts: Influenza” web section for the 2024–25 influenza season (#IZX12)
* Recap: Immunize.org adds new PCV21 to “Ask the Experts: Pneumococcal” web section (#IZX13)
* Recap: Immunize.org adds new vaccines to popular resource “Before You Vaccinate Adults, Consider Their ‘H-A-L-O’!” (#IZX14)
* Recap: Immunize.org updates “Vaccines with Diluents: How to Use Them” resource (#IZX15)
Featured Resources
* Champions for Vaccine Education, Equity, and Progress releases “Stay Updated” campaign to explain the importance of receiving updated COVID-19 and influenza vaccines (#IZX16)
* Explore the www.Give2MenACWY.org website to increase coverage for the meningococcal ACWY booster and other adolescent vaccinations (#IZX17)
Notable Publications
* “Back to School Means Updating Childhood Vaccines” published in Clinical Advisor (#IZX18)
Upcoming Events
* Virtual: Watch September 12–13 National Vaccine Advisory Committee meeting addressing hepatitis B, tuberculosis, and HIV vaccines (#IZX19)
Editorial Information (#Editorial)
------------------------------------------------------------
Top Stories
------------------------------------------------------------
“Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2024–25 Influenza Season” published in MMWR
CDC published Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2024–25 Influenza Season ([link removed]) on August 29 in MMWR Recommendations and Reports. A portion of the summary appears below.
All persons should receive an age-appropriate influenza vaccine (i.e., one approved for their age), with the exception that solid organ transplant recipients aged 18 through 64 years who are receiving immunosuppressive medication regimens may receive either high-dose inactivated influenza vaccine (HD-IIV3) or adjuvanted inactivated influenza vaccine (aIIV3) as acceptable options (without a preference over other age-appropriate IIV3s or RIV3). Except for vaccination for adults aged ≥65 years, ACIP makes no preferential recommendation for a specific vaccine when more than one licensed and recommended vaccine is available. ACIP recommends that adults aged ≥65 years preferentially receive any one of the following higher dose or adjuvanted influenza vaccines: trivalent high-dose inactivated influenza vaccine (HD-IIV3), trivalent recombinant influenza vaccine (RIV3), or trivalent adjuvanted inactivated influenza vaccine (aIIV3). If none of these three vaccines is available at an opportunity for
vaccine administration, then any other age-appropriate influenza vaccine should be used.
[link removed]
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]) .
Related Links
* CDC: MMWR main page ([link removed]) providing access to the MMWR family of publications
* CDC: ACIP Recommendations: Influenza (Flu) Vaccine ([link removed]) main page
* Immunize.org: Vaccines A–Z: Influenza ([link removed]) main page
Back to top (#Top)
------------------------------------------------------------
FDA authorizes updated protein-based Novavax COVID-19 vaccine for people age 12 years and older to better protect against currently circulating variants
On August 30, one week after approving the 2024–25 mRNA COVID-19 vaccines, FDA authorized use of the 2024–25 formulation of the protein-based Novavax COVID-19 vaccine ([link removed]) . The new formulation contains a single antigen that corresponds to the Omicron variant JN.1 strain of SARS-CoV-2. Because the Novavax COVID-19 vaccine continues to be used only under the terms of an emergency use authorization (EUA), those who administer it should refer to the FDA’s updated EUA Fact Sheet for Healthcare Providers Administering Vaccine ([link removed]) and provide recipients with FDA’s updated EUA Fact Sheet for Recipients and Caregivers ([link removed]) . Novavax COVID-19 vaccine is authorized for use in people age 12 years and older.
At its June 2024 meeting, ACIP voted in advance to recommend use of 2024–25 COVID-19 vaccines in the manner licensed or authorized by FDA. Therefore, clinicians may begin using any of the 2024–25 COVID-19 vaccines as indicated by FDA as soon as they receive them. A portion of the recent FDA press release appears below.
What You Need to Know
* Individuals 12 years of age and older who have never been vaccinated with any COVID-19 vaccine are eligible to receive two doses of this updated [Novavax] vaccine, 3 weeks apart
* Individuals who have been vaccinated only with one dose of any Novavax COVID-19 vaccine are eligible to receive one dose of the updated Novavax COVID-19 vaccine at least 3 weeks after the previous dose
* Those who have been vaccinated with a prior formula of a COVID-19 vaccine from another manufacturer or with two or more doses of a prior formula of the Novavax COVID-19 vaccine are eligible to receive a single dose of the updated Novavax COVID-19 vaccine at least 2 months after the last dose of a COVID-19 vaccine
On August 23, CDC posted interim clinical considerations for COVID-19 vaccines ([link removed]) for the current season. Immunize.org is in the process of revising our COVID-19 content. We will post online and announce in IZ Express new standing orders templates from CDC for the use of 2024–25 Novavax COVID-19 vaccine as soon as they are available. These updates are reflected in the September revision of Immunize.org’s Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools ([link removed]) .
Do not administer any remaining doses of any 2023–24 COVID-19 vaccine; if you have any, remove them from storage units and dispose of them or return them as appropriate.
Related Links
* FDA: FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect against Currently Circulating Variants ([link removed]) (8/30/24)
* FDA: Novavax COVID-19 Vaccine, Adjuvanted ([link removed]) (2024–2025 Formula)
* CDC: Use of COVID-19 Vaccines in the United States: Interim Clinical Considerations ([link removed])
Back to top (#Top)
------------------------------------------------------------
Immunize.org updates “Ask the Experts: RSV (Respiratory Syncytial Virus)” web section for the 2024–25 season
Immunize.org updated its popular Ask the Experts: RSV (Respiratory Syncytial Virus) ([link removed]) web page to reflect the 2024 ACIP recommendations for RSV vaccination of older adults. Content has been updated to include the newest RSV vaccine, the mRNA vaccine, mResvia (Moderna). The content also now addresses the recently published updated ACIP recommendations for older adults, including the routine recommendation for one dose of RSV vaccine for all adults age 75 years or older and the recommendation for one dose of RSV vaccine for adults age 60 through 74 who are at increased risk of severe RSV disease.
[link removed]
Immunize.org’s Ask the Experts ([link removed]) main page leads you to 30 web pages on various topics with more than 1,300 common or challenging questions and answers about vaccines and their administration. Immunize.org’s team of experts includes Kelly L. Moore, MD, MPH (team lead); Carolyn B. Bridges, MD, FACP; Iyabode Beysolow, MD, MPH; and Jane R. Zucker, MD, MPH.
Related Link
* Immunize.org: Ask the Experts ([link removed]) main page with more than 1,300 questions and answers
Back to top (#Top)
------------------------------------------------------------
Immunize.org updates “Vaccinations for Adults: You’re Never Too Old to Get Vaccinated!” handout with current pneumococcal and RSV recommendations
Immunize.org updated its Vaccinations for Adults: You’re Never Too Old to Get Vaccinated! ([link removed]) This handout now includes the recently updated recommendations for routine RSV vaccination of adults age 75 years and older, as well as risk-based recommendations for adults age 60–74 years. Information on pneumococcal vaccines was reworded for greater clarity.
[link removed]
Related Links
* Immunize.org: Clinical Resources: Adult Vaccination ([link removed]) main page
* Immunize.org: Clinical Resources A–Z ([link removed]) main page, where you can filter by topic, vaccine, language, or other criteria
Back to top (#Top)
------------------------------------------------------------
Immunize.org updates the Spanish translations of 2024–25 screening checklists for contraindications to injectable and nasal influenza vaccines
Immunize.org updated its Spanish translations of screening checklists for the 2024–25 influenza season ([link removed]) .
* Screening Checklist for Contraindications to Injectable Influenza Vaccination ([link removed]) (view in English ([link removed]) )
* Screening Checklist for Contraindications to Live Attenuated Intranasal Influenza Vaccination ([link removed]) (view in English ([link removed]) )
References to the number of influenza virus strains in the vaccines were removed because all vaccines for this season contain three strains, two influenza A and one influenza B strain. The B/Yamagata strain is no longer included because it is not detected anywhere in the world.
[link removed] [link removed]
Related Links
* Immunize.org: Vaccines A–Z: Influenza ([link removed]) main page
* Immunize.org: Clinical Resources: Screening Checklists ([link removed]) main page
* Immunize.org: Clinical Resources: Sp ([link removed]) anish Translations ([link removed]) main page
* Immunize.org: Clinical Resources A–Z ([link removed]) main page, where you can filter by topic, vaccine, language, or other criteria
Back to top (#Top)
------------------------------------------------------------
CDC’s Bridge Access Program to provide free COVID-19 vaccines to uninsured or underinsured adults ended
CDC’s Bridge Access Program ([link removed]) to provide COVID-19 vaccination for uninsured or underinsured adults ended in August 2024 due to a loss of funding. Limited federal funds have been made available to state public health departments to support the purchase some of the 2024–25 updated COVID-19 vaccines for this population.
In the absence of the Bridge Access Program, uninsured adults seeking the 2024–25 COVID-19 vaccine should contact their state or local health department immunization programs ([link removed]) for additional information about affordable access options in their area.
The 2024–25 COVID-19 vaccines remain accessible with no out-of-pocket cost through in-network vaccination providers to Medicaid and Medicare recipients and to adults with commercial insurance compliant with the Affordable Care Act. Children and teens younger than age 19 years who are uninsured or underinsured, or American Indian or Alaska Native, continue to have access to these vaccines at no cost through the federal Vaccines for Children program.
Back to top (#Top)
------------------------------------------------------------
Watch and share the latest installment in Immunize.org’s Orientation Video Series: Introducing Immunize.org (mobile view) to see how our new mobile site looks on your smartphone!
Immunize.org is pleased to share a new version of Introducing Immunize.org, a 3-minute video introducing our website ([link removed]) , that shows you how the new mobile version of the site looks on your smartphone. This video provides a quick overview of our organization, mission, website, and the resources we offer to support effective immunization practices.
Available now on our YouTube channel ([link removed]) , this is part of our new Orientation Video Series ([link removed]) . Each orientation video will be made available in a horizontal version (formatted for desktops) and a vertical version (for smart phones) to help you become familiar with the new look and navigation of the website.
[link removed]
Please share this video with anyone who needs to learn how to get the most out of Immunize.org’s website to support effective immunization practices.
Like, follow, and share Immunize.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise.
* Facebook at ImmunizeOrg ([link removed])
* Instagram at ImmunizeOrg ([link removed])
* LinkedIn at ImmunizeOrg ([link removed])
* YouTube at ImmunizeOrg ([link removed])
Back to top (#Top)
------------------------------------------------------------
IZ Express keeps 54,000+ readers up to date on what’s new in vaccines each week; invite your colleagues to subscribe
Encourage your coworkers to subscribe to ([link removed]) IZ Express ([link removed]) ([link removed]) so they get all the news that matters to vaccinators in their own inbox each Wednesday. IZ Express, the weekly e-newsletter produced by Immunize.org, alerts 54,000+ readers to the week’s important vaccine developments. IZ Express also features:
* Educational materials from Immunize.org, CDC, AAP, and others
* Newly posted VISs and their translations
* Notices about online and in-person educational opportunities, many offering free continuing education credit
[link removed]
We appreciate you as a subscriber! Thank you for helping us get the latest vaccine news to every clinical and public health professional who needs to know.
Back to top (#Top)
------------------------------------------------------------
Journalists interview Immunize.org experts
Journalists seek out Immunize.org experts to help explain vaccines to the public and policy makers. We help the media understand and communicate the complex work vaccinators do. Here is a selection of our recent citations.
* Salon: New COVID Vaccines Have Arrived Just as a Vaccine Equity Program Is Ending ([link removed]) (8/28/24)
* KFF Health News: The New COVID Vaccine Is Out. Why You Might Not Want to Rush to Get It. ([link removed]) (8/26/24)
Back to top (#Top)
------------------------------------------------------------
Vaccines in the news
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* Pharmacy Times: Immunization Awareness Month Highlights the Role of Pharmacies ([link removed]) (8/29/24)
* Axios: Vaccine Hesitancy Eats into Back-to-School Shots ([link removed]) (8/27/24)
* Time: You’re More Likely to Get Heart Issues from COVID-19 than the Vaccine ([link removed]) (8/26/24)
* STAT: To Stop Mpox from Becoming the Next Pandemic, We Must Address Global Vaccine Inequities ([link removed]) (8/17/24)
Back to top (#Top)
------------------------------------------------------------
Immunize.org Website and Clinical Resources
------------------------------------------------------------
Spotlight on the website: Ask the Experts video questions and answers
This week’s Spotlight features a new way to experience Ask the Experts questions and answers. Short videos recorded by Dr. Kelly Moore have been available for some time on our Videos page and our YouTube channel ([link removed]) . Now these are integrated into the Ask the Experts section of our website and are searchable using the filter functions already available for our written content.
Each video includes a preview image linked to the full video. The video duration and a link to view all video questions is listed below the image. Currently, there are 36 Ask the Expert videos, and more will be added in the future.
[link removed]
In the Ask the Experts section of the website, video and traditional text question-and-answers are intermixed. Both can be viewed by topic or in the search and filter results. If you prefer only video results, use shortcuts to view only videos on the Ask the Experts main menu tab and left-side menu.
We hope you continue to find Ask the Experts to be a valuable resource and that these enhancements will help you more easily find relevant answers to your questions about vaccines and vaccine administration.
Back to top (#Top)
------------------------------------------------------------
Recap: Immunize.org updates “Ask the Experts: Influenza” web section for the 2024–25 influenza season
Immunize.org updated all the questions and answers on its popular Ask the Experts: Influenza ([link removed]) web page. Clinical content now reflects 2024–25 influenza season recommendations. Changes include:
* References to the 2024–25 trivalent vaccines (containing two influenza A and one influenza B virus vaccine antigen) following removal of the B/Yamagata virus from the vaccine because it is no longer circulating
* Unless necessary for understanding, references to the number of strains in vaccines (also called “valency”) were removed
* ACIP affirmation that everyone age 6 months and older who has an egg allergy may receive any age-appropriate influenza vaccine without special precautions
* ACIP allowance for off-label use of high-dose (HD-IIV, Fluzone High-Dose, Sanofi) or adjuvanted influenza vaccine (aIIV, Fluad, CSL Seqirus) as an option for solid organ transplant recipients age 18 through 64 years who are on immunosuppressive medication regimens, without a preference over any other age-appropriate injectable influenza vaccine
* Updated hyperlinks, as needed
[link removed]
Immunize.org’s Ask the Experts ([link removed]) main page leads you to 30 web pages on various topics with more than 1,300 common or challenging questions and answers about vaccines and their administration. Immunize.org’s team of experts includes Kelly L. Moore, MD, MPH (team lead); Carolyn B. Bridges, MD, FACP; Iyabode Beysolow, MD, MPH; and Jane R. Zucker, MD, MPH.
Related Link
* Immunize.org: Ask the Experts ([link removed]) main page with more than 1,300 questions and answers
Back to top (#Top)
------------------------------------------------------------
Recap: Immunize.org adds new PCV21 to “Ask the Experts: Pneumococcal” web section
Immunize.org updated all the questions and answers on its popular Ask the Experts: Pneumococcal ([link removed]) web page. The clinical content now reflects updated recommendations for PCV21 vaccine (Capvaxive, Merck) as an option for adults age 18 years or older who are recommended to receive a pneumococcal conjugate vaccine. Hyperlinks were also updated as needed.
[link removed]
Immunize.org’s Ask the Experts ([link removed]) main page leads you to 30 web pages on various topics with more than 1,300 common or challenging questions and answers about vaccines and their administration. Immunize.org’s team of experts includes Kelly L. Moore, MD, MPH (team lead); Carolyn B. Bridges, MD, FACP; Iyabode Beysolow, MD, MPH; and Jane R. Zucker, MD, MPH.
Related Link
* Immunize.org: Ask the Experts ([link removed]) main page with more than 1,300 questions and answers
Back to top (#Top)
------------------------------------------------------------
Recap: Immunize.org adds new vaccines to popular resource “Before You Vaccinate Adults, Consider Their ‘H-A-L-O’!”
Immunize.org recently updated its resource for healthcare professionals titled Before You Vaccinate Adults, Consider Their “H-A-L-O” ([link removed]) !
H-A-L-O refers to four factors:
* Health condition
* Age
* Lifestyle
* Occupation
The document now includes mpox vaccine and updated polio (IPV) vaccination recommendations for previously unvaccinated adults. The RSV vaccine section was revised to match the June 2024 ACIP recommendations for routine vaccination of adults age 75 years and older, and risk-based vaccination of adults age 60 through 74 years.
[link removed]
Related Links
* Immunize.org: Clinic Tools: Vaccine Recommendations ([link removed]) web page
* Immunize.org: Clinical Resources A–Z ([link removed]) main page, where you can filter by topic, vaccine, language, or other criteria
Back to top (#Top)
------------------------------------------------------------
Recap: Immunize.org updates “Vaccines with Diluents: How to Use Them” resource
Immunize.org recently added Penbraya (MenABCWY, Pfizer) to its Vaccines with Diluents: How to Use Them ([link removed]) and updated the resource to specify the formulation of Pfizer-BioNTech COVID-19 vaccine that requires dilution.
[link removed]
Related Links
* Immunize.org: Clinical Resources: Storage & Handling ([link removed]) main page
* Immunize.org: Clinical Resources A–Z ([link removed]) main page, where you can filter by topic, vaccine, language, or other criteria
Back to top (#Top)
------------------------------------------------------------
Featured Resources
------------------------------------------------------------
Champions for Vaccine Education, Equity, and Progress releases “Stay Updated” campaign to explain the importance of receiving updated COVID-19 and influenza vaccines
Champions for Vaccine Education, Equity, and Progress ([link removed]) (CVEEP), led by the Alliance for Aging Research, HealthyWomen, and the National Caucus and Center on Black Aging, released its Stay Updated ([link removed]) campaign. This promotion highlights the importance of receiving updated COVID-19 and influenza vaccines this season. This campaign offers fact sheets, an informational poster, a glossary of virology terms, and an information sheet on milestones in COVID-19 vaccination.
[link removed]
Visit CVEEP's Stay Updated campaign ([link removed]) to learn more about the need for updated vaccines and access resources to encourage your community to stay protected.
Back to top (#Top)
------------------------------------------------------------
Explore the www.Give2MenACWY.org website to increase coverage for the meningococcal ACWY booster and other adolescent vaccinations
Immunize.org's www.Give2MenACWY.org ([link removed]) website promotes the importance of adolescent vaccination, including the recommended MenACWY vaccine booster dose at age 16. Many teens are behind on vaccines because of the pandemic, so vaccine outreach is more important than ever.
Materials on this colorful website for healthcare professionals incorporate the 2020 ACIP meningococcal vaccine recommendations ([link removed]) and coverage statistics from CDC’s National Immunization Survey–Teen (NIS–Teen). One particularly popular resource on the site is the Algorithm for MenACWY Immunization in Adolescents 11 through 18 Years of Age ([link removed]) .
[link removed]
The website is divided into five easy-to-access sections:
* Vaccinate Teens ([link removed]) – Teen vaccination schedules and tips for improving vaccination rates
* Give 2 Doses ([link removed]) – Tools to help improve second dose coverage of MenACWY vaccine
* 16-Year-Old Visit ([link removed]) – Resources to help providers and patients remember the important vaccines recommended for 16-year-olds
* Tools for Providers ([link removed]) – Tools to explain meningococcal ACWY vaccine recommendations and improve coverage for all adolescent vaccines
* Resources ([link removed]) – Links to print materials ([link removed]) , organizations ([link removed]) involved in adolescent vaccination, personal stories ([link removed]) about the importance of vaccination, and other resources ([link removed]) of interest
The site also categorizes materials ([link removed]) according to whether they are primarily of interest to providers, to adolescents, or to parents.
Visit Give2MenACWY.org ([link removed]) and enjoy browsing (and deploying) its bountiful resources.
Related Links
* Give2MenACWY.org ([link removed]) website
* Algorithm for MenACWY Immunization in Adolescents 11–18 Years of Age ([link removed])
* MenACWY: You're Not Done If You Give Just One: Give 2 Doses to Strengthen Protection ([link removed])
* Recommending MenACWY: What to Say and How to Say It ([link removed])
* Top 10 Ways to Improve Adolescent Immunization Rates ([link removed])
* Developing an Immunization Culture in Your Office ([link removed])
* Know Your Rates: Measuring Immunization Success in Your Practice ([link removed])
* You're 16: We Recommend These Vaccines for You ([link removed])
* Dear Colleague Letter: 16-Year-Old Patients: Make Sure They Receive Their Annual Well Visit and Vaccinations ([link removed]) – signed by six medical societies
* Ask the Experts: Meningococcal ACWY ([link removed])
* CDC: ACIP Meningococcal Vaccine Recommendations ([link removed])
* CDC: Vaccination Coverage Among Adolescents Aged 13–17 Years—National Immunization Survey–Teen, United States, 2023 ([link removed])
Back to top (#Top)
------------------------------------------------------------
Notable Publications
------------------------------------------------------------
“Back to School Means Updating Childhood Vaccines” published in Clinical Advisor
In its August 23 issue, Clinical Advisor published Back to School Means Updating Childhood Vaccines ([link removed]) . This article was written by Immunize.org’s Mary Beth Koslap-Petraco, DNP, FAANP. The introduction paragraph appears below.
The lazy, crazy days of summer are drawing to a close and it is time to start thinking about back to school and all that entails to prepare students to optimize their health. Vaccines can be number one on the list. We need to take a serious look at how the number of children who receive all necessary vaccines for school has dropped since the COVID-19 pandemic began its devastating march around the world. The immunization rates are even lower in children who are eligible for the Vaccines for Children (VFC) program. This federal program provides no-cost vaccines to children who are uninsured or are Medicaid eligible. In some states VFC also covers children whose insurance does not cover vaccines. It is time to review what vaccines are indicated to keep all students healthy and practice some infection prevention.
Back to top (#Top)
------------------------------------------------------------
Upcoming Events
------------------------------------------------------------
Virtual: Watch September 12–13 National Vaccine Advisory Committee meeting addressing hepatitis B, tuberculosis, and HIV vaccines
National Vaccine Advisory Committee (NVAC) meetings ([link removed]) are held three times each year to address pressing topics affecting the vaccine enterprise. The September 12–13 NVAC agenda ([link removed]) topics include implementation of the universal hepatitis B vaccine recommendations for adults age 19–59 years, new approaches for tuberculosis vaccine innovation, and research to inform future HIV vaccine development. NVAC will also host panels on vaccine equity, provider payment, and planning for the development of the next national vaccine strategy.
The hepatitis B panel will include Immunize.org CEO, Kelly L. Moore, MD, MPH, discussing challenges and opportunities to increase HepB coverage in adults.
NVAC meetings are open to the public and can be viewed virtually. Preregistration ([link removed]) is required for both public attendance and comment.
View the September 12–13 NVAC Meeting ([link removed]) web page for more information.
Back to top (#Top)
------------------------------------------------------------
For more upcoming events, visit our Calendar of Events ([link removed]) .
Editorial Information
Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Grabenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Kayla Ohlde
About IZ Express
Immunize.org welcomes redistribution of this issue of IZ Express or selected articles.
When you do so, please add a note that Immunize.org is the source of the material and provide a link to this issue ([link removed]) .
IZ Express is supported in part by Grant No. 1NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer ([link removed])
ISSN: 2771-8085
This email was sent to [email protected] (mailto:[email protected])
why did I get this? ([link removed]) unsubscribe from this list ([link removed]) update subscription preferences ([link removed])
Immunize.org . 2136 Ford Parkway . Suite 5011 . Saint Paul, MN 55116 . USA
Email not displaying correctly? View it in your browser. ([link removed])
[link removed]
Issue 1,773: September 4, 2024
Top Stories
* “Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2024–25 Influenza Season” published in MMWR (#IZX1)
* FDA authorizes updated protein-based Novavax COVID-19 vaccine for people age 12 years and older to better protect against currently circulating variants (#IZX2)
* Immunize.org updates “Ask the Experts: RSV (Respiratory Syncytial Virus)” web section for the 2024–25 season (#IZX3)
* Immunize.org updates “Vaccinations for Adults: You’re Never Too Old to Get Vaccinated!” handout with current pneumococcal and RSV recommendations (#IZX4)
* Immunize.org updates the Spanish translations of 2024–25 screening checklists for contraindications to injectable and nasal influenza vaccines (#IZX5)
* CDC’s Bridge Access Program to provide free COVID-19 vaccines to uninsured or underinsured adults ended (#IZX6)
* Watch and share the latest installment in Immunize.org’s Orientation Video Series: Introducing Immunize.org (mobile view) to see how our new mobile site looks on your smartphone! (#IZX7)
* IZ Express keeps 54,000+ readers up to date on what’s new in vaccines each week; invite your colleagues to subscribe (#IZX8)
* Journalists interview Immunize.org experts (#IZX9)
* Vaccines in the news (#IZX10)
Immunize.org Website and Clinical Resources
* Spotlight on the website: Ask the Experts video questions and answers (#IZX11)
* Recap: Immunize.org updates “Ask the Experts: Influenza” web section for the 2024–25 influenza season (#IZX12)
* Recap: Immunize.org adds new PCV21 to “Ask the Experts: Pneumococcal” web section (#IZX13)
* Recap: Immunize.org adds new vaccines to popular resource “Before You Vaccinate Adults, Consider Their ‘H-A-L-O’!” (#IZX14)
* Recap: Immunize.org updates “Vaccines with Diluents: How to Use Them” resource (#IZX15)
Featured Resources
* Champions for Vaccine Education, Equity, and Progress releases “Stay Updated” campaign to explain the importance of receiving updated COVID-19 and influenza vaccines (#IZX16)
* Explore the www.Give2MenACWY.org website to increase coverage for the meningococcal ACWY booster and other adolescent vaccinations (#IZX17)
Notable Publications
* “Back to School Means Updating Childhood Vaccines” published in Clinical Advisor (#IZX18)
Upcoming Events
* Virtual: Watch September 12–13 National Vaccine Advisory Committee meeting addressing hepatitis B, tuberculosis, and HIV vaccines (#IZX19)
Editorial Information (#Editorial)
------------------------------------------------------------
Top Stories
------------------------------------------------------------
“Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2024–25 Influenza Season” published in MMWR
CDC published Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2024–25 Influenza Season ([link removed]) on August 29 in MMWR Recommendations and Reports. A portion of the summary appears below.
All persons should receive an age-appropriate influenza vaccine (i.e., one approved for their age), with the exception that solid organ transplant recipients aged 18 through 64 years who are receiving immunosuppressive medication regimens may receive either high-dose inactivated influenza vaccine (HD-IIV3) or adjuvanted inactivated influenza vaccine (aIIV3) as acceptable options (without a preference over other age-appropriate IIV3s or RIV3). Except for vaccination for adults aged ≥65 years, ACIP makes no preferential recommendation for a specific vaccine when more than one licensed and recommended vaccine is available. ACIP recommends that adults aged ≥65 years preferentially receive any one of the following higher dose or adjuvanted influenza vaccines: trivalent high-dose inactivated influenza vaccine (HD-IIV3), trivalent recombinant influenza vaccine (RIV3), or trivalent adjuvanted inactivated influenza vaccine (aIIV3). If none of these three vaccines is available at an opportunity for
vaccine administration, then any other age-appropriate influenza vaccine should be used.
[link removed]
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]) .
Related Links
* CDC: MMWR main page ([link removed]) providing access to the MMWR family of publications
* CDC: ACIP Recommendations: Influenza (Flu) Vaccine ([link removed]) main page
* Immunize.org: Vaccines A–Z: Influenza ([link removed]) main page
Back to top (#Top)
------------------------------------------------------------
FDA authorizes updated protein-based Novavax COVID-19 vaccine for people age 12 years and older to better protect against currently circulating variants
On August 30, one week after approving the 2024–25 mRNA COVID-19 vaccines, FDA authorized use of the 2024–25 formulation of the protein-based Novavax COVID-19 vaccine ([link removed]) . The new formulation contains a single antigen that corresponds to the Omicron variant JN.1 strain of SARS-CoV-2. Because the Novavax COVID-19 vaccine continues to be used only under the terms of an emergency use authorization (EUA), those who administer it should refer to the FDA’s updated EUA Fact Sheet for Healthcare Providers Administering Vaccine ([link removed]) and provide recipients with FDA’s updated EUA Fact Sheet for Recipients and Caregivers ([link removed]) . Novavax COVID-19 vaccine is authorized for use in people age 12 years and older.
At its June 2024 meeting, ACIP voted in advance to recommend use of 2024–25 COVID-19 vaccines in the manner licensed or authorized by FDA. Therefore, clinicians may begin using any of the 2024–25 COVID-19 vaccines as indicated by FDA as soon as they receive them. A portion of the recent FDA press release appears below.
What You Need to Know
* Individuals 12 years of age and older who have never been vaccinated with any COVID-19 vaccine are eligible to receive two doses of this updated [Novavax] vaccine, 3 weeks apart
* Individuals who have been vaccinated only with one dose of any Novavax COVID-19 vaccine are eligible to receive one dose of the updated Novavax COVID-19 vaccine at least 3 weeks after the previous dose
* Those who have been vaccinated with a prior formula of a COVID-19 vaccine from another manufacturer or with two or more doses of a prior formula of the Novavax COVID-19 vaccine are eligible to receive a single dose of the updated Novavax COVID-19 vaccine at least 2 months after the last dose of a COVID-19 vaccine
On August 23, CDC posted interim clinical considerations for COVID-19 vaccines ([link removed]) for the current season. Immunize.org is in the process of revising our COVID-19 content. We will post online and announce in IZ Express new standing orders templates from CDC for the use of 2024–25 Novavax COVID-19 vaccine as soon as they are available. These updates are reflected in the September revision of Immunize.org’s Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools ([link removed]) .
Do not administer any remaining doses of any 2023–24 COVID-19 vaccine; if you have any, remove them from storage units and dispose of them or return them as appropriate.
Related Links
* FDA: FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect against Currently Circulating Variants ([link removed]) (8/30/24)
* FDA: Novavax COVID-19 Vaccine, Adjuvanted ([link removed]) (2024–2025 Formula)
* CDC: Use of COVID-19 Vaccines in the United States: Interim Clinical Considerations ([link removed])
Back to top (#Top)
------------------------------------------------------------
Immunize.org updates “Ask the Experts: RSV (Respiratory Syncytial Virus)” web section for the 2024–25 season
Immunize.org updated its popular Ask the Experts: RSV (Respiratory Syncytial Virus) ([link removed]) web page to reflect the 2024 ACIP recommendations for RSV vaccination of older adults. Content has been updated to include the newest RSV vaccine, the mRNA vaccine, mResvia (Moderna). The content also now addresses the recently published updated ACIP recommendations for older adults, including the routine recommendation for one dose of RSV vaccine for all adults age 75 years or older and the recommendation for one dose of RSV vaccine for adults age 60 through 74 who are at increased risk of severe RSV disease.
[link removed]
Immunize.org’s Ask the Experts ([link removed]) main page leads you to 30 web pages on various topics with more than 1,300 common or challenging questions and answers about vaccines and their administration. Immunize.org’s team of experts includes Kelly L. Moore, MD, MPH (team lead); Carolyn B. Bridges, MD, FACP; Iyabode Beysolow, MD, MPH; and Jane R. Zucker, MD, MPH.
Related Link
* Immunize.org: Ask the Experts ([link removed]) main page with more than 1,300 questions and answers
Back to top (#Top)
------------------------------------------------------------
Immunize.org updates “Vaccinations for Adults: You’re Never Too Old to Get Vaccinated!” handout with current pneumococcal and RSV recommendations
Immunize.org updated its Vaccinations for Adults: You’re Never Too Old to Get Vaccinated! ([link removed]) This handout now includes the recently updated recommendations for routine RSV vaccination of adults age 75 years and older, as well as risk-based recommendations for adults age 60–74 years. Information on pneumococcal vaccines was reworded for greater clarity.
[link removed]
Related Links
* Immunize.org: Clinical Resources: Adult Vaccination ([link removed]) main page
* Immunize.org: Clinical Resources A–Z ([link removed]) main page, where you can filter by topic, vaccine, language, or other criteria
Back to top (#Top)
------------------------------------------------------------
Immunize.org updates the Spanish translations of 2024–25 screening checklists for contraindications to injectable and nasal influenza vaccines
Immunize.org updated its Spanish translations of screening checklists for the 2024–25 influenza season ([link removed]) .
* Screening Checklist for Contraindications to Injectable Influenza Vaccination ([link removed]) (view in English ([link removed]) )
* Screening Checklist for Contraindications to Live Attenuated Intranasal Influenza Vaccination ([link removed]) (view in English ([link removed]) )
References to the number of influenza virus strains in the vaccines were removed because all vaccines for this season contain three strains, two influenza A and one influenza B strain. The B/Yamagata strain is no longer included because it is not detected anywhere in the world.
[link removed] [link removed]
Related Links
* Immunize.org: Vaccines A–Z: Influenza ([link removed]) main page
* Immunize.org: Clinical Resources: Screening Checklists ([link removed]) main page
* Immunize.org: Clinical Resources: Sp ([link removed]) anish Translations ([link removed]) main page
* Immunize.org: Clinical Resources A–Z ([link removed]) main page, where you can filter by topic, vaccine, language, or other criteria
Back to top (#Top)
------------------------------------------------------------
CDC’s Bridge Access Program to provide free COVID-19 vaccines to uninsured or underinsured adults ended
CDC’s Bridge Access Program ([link removed]) to provide COVID-19 vaccination for uninsured or underinsured adults ended in August 2024 due to a loss of funding. Limited federal funds have been made available to state public health departments to support the purchase some of the 2024–25 updated COVID-19 vaccines for this population.
In the absence of the Bridge Access Program, uninsured adults seeking the 2024–25 COVID-19 vaccine should contact their state or local health department immunization programs ([link removed]) for additional information about affordable access options in their area.
The 2024–25 COVID-19 vaccines remain accessible with no out-of-pocket cost through in-network vaccination providers to Medicaid and Medicare recipients and to adults with commercial insurance compliant with the Affordable Care Act. Children and teens younger than age 19 years who are uninsured or underinsured, or American Indian or Alaska Native, continue to have access to these vaccines at no cost through the federal Vaccines for Children program.
Back to top (#Top)
------------------------------------------------------------
Watch and share the latest installment in Immunize.org’s Orientation Video Series: Introducing Immunize.org (mobile view) to see how our new mobile site looks on your smartphone!
Immunize.org is pleased to share a new version of Introducing Immunize.org, a 3-minute video introducing our website ([link removed]) , that shows you how the new mobile version of the site looks on your smartphone. This video provides a quick overview of our organization, mission, website, and the resources we offer to support effective immunization practices.
Available now on our YouTube channel ([link removed]) , this is part of our new Orientation Video Series ([link removed]) . Each orientation video will be made available in a horizontal version (formatted for desktops) and a vertical version (for smart phones) to help you become familiar with the new look and navigation of the website.
[link removed]
Please share this video with anyone who needs to learn how to get the most out of Immunize.org’s website to support effective immunization practices.
Like, follow, and share Immunize.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise.
* Facebook at ImmunizeOrg ([link removed])
* Instagram at ImmunizeOrg ([link removed])
* LinkedIn at ImmunizeOrg ([link removed])
* YouTube at ImmunizeOrg ([link removed])
Back to top (#Top)
------------------------------------------------------------
IZ Express keeps 54,000+ readers up to date on what’s new in vaccines each week; invite your colleagues to subscribe
Encourage your coworkers to subscribe to ([link removed]) IZ Express ([link removed]) ([link removed]) so they get all the news that matters to vaccinators in their own inbox each Wednesday. IZ Express, the weekly e-newsletter produced by Immunize.org, alerts 54,000+ readers to the week’s important vaccine developments. IZ Express also features:
* Educational materials from Immunize.org, CDC, AAP, and others
* Newly posted VISs and their translations
* Notices about online and in-person educational opportunities, many offering free continuing education credit
[link removed]
We appreciate you as a subscriber! Thank you for helping us get the latest vaccine news to every clinical and public health professional who needs to know.
Back to top (#Top)
------------------------------------------------------------
Journalists interview Immunize.org experts
Journalists seek out Immunize.org experts to help explain vaccines to the public and policy makers. We help the media understand and communicate the complex work vaccinators do. Here is a selection of our recent citations.
* Salon: New COVID Vaccines Have Arrived Just as a Vaccine Equity Program Is Ending ([link removed]) (8/28/24)
* KFF Health News: The New COVID Vaccine Is Out. Why You Might Not Want to Rush to Get It. ([link removed]) (8/26/24)
Back to top (#Top)
------------------------------------------------------------
Vaccines in the news
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* Pharmacy Times: Immunization Awareness Month Highlights the Role of Pharmacies ([link removed]) (8/29/24)
* Axios: Vaccine Hesitancy Eats into Back-to-School Shots ([link removed]) (8/27/24)
* Time: You’re More Likely to Get Heart Issues from COVID-19 than the Vaccine ([link removed]) (8/26/24)
* STAT: To Stop Mpox from Becoming the Next Pandemic, We Must Address Global Vaccine Inequities ([link removed]) (8/17/24)
Back to top (#Top)
------------------------------------------------------------
Immunize.org Website and Clinical Resources
------------------------------------------------------------
Spotlight on the website: Ask the Experts video questions and answers
This week’s Spotlight features a new way to experience Ask the Experts questions and answers. Short videos recorded by Dr. Kelly Moore have been available for some time on our Videos page and our YouTube channel ([link removed]) . Now these are integrated into the Ask the Experts section of our website and are searchable using the filter functions already available for our written content.
Each video includes a preview image linked to the full video. The video duration and a link to view all video questions is listed below the image. Currently, there are 36 Ask the Expert videos, and more will be added in the future.
[link removed]
In the Ask the Experts section of the website, video and traditional text question-and-answers are intermixed. Both can be viewed by topic or in the search and filter results. If you prefer only video results, use shortcuts to view only videos on the Ask the Experts main menu tab and left-side menu.
We hope you continue to find Ask the Experts to be a valuable resource and that these enhancements will help you more easily find relevant answers to your questions about vaccines and vaccine administration.
Back to top (#Top)
------------------------------------------------------------
Recap: Immunize.org updates “Ask the Experts: Influenza” web section for the 2024–25 influenza season
Immunize.org updated all the questions and answers on its popular Ask the Experts: Influenza ([link removed]) web page. Clinical content now reflects 2024–25 influenza season recommendations. Changes include:
* References to the 2024–25 trivalent vaccines (containing two influenza A and one influenza B virus vaccine antigen) following removal of the B/Yamagata virus from the vaccine because it is no longer circulating
* Unless necessary for understanding, references to the number of strains in vaccines (also called “valency”) were removed
* ACIP affirmation that everyone age 6 months and older who has an egg allergy may receive any age-appropriate influenza vaccine without special precautions
* ACIP allowance for off-label use of high-dose (HD-IIV, Fluzone High-Dose, Sanofi) or adjuvanted influenza vaccine (aIIV, Fluad, CSL Seqirus) as an option for solid organ transplant recipients age 18 through 64 years who are on immunosuppressive medication regimens, without a preference over any other age-appropriate injectable influenza vaccine
* Updated hyperlinks, as needed
[link removed]
Immunize.org’s Ask the Experts ([link removed]) main page leads you to 30 web pages on various topics with more than 1,300 common or challenging questions and answers about vaccines and their administration. Immunize.org’s team of experts includes Kelly L. Moore, MD, MPH (team lead); Carolyn B. Bridges, MD, FACP; Iyabode Beysolow, MD, MPH; and Jane R. Zucker, MD, MPH.
Related Link
* Immunize.org: Ask the Experts ([link removed]) main page with more than 1,300 questions and answers
Back to top (#Top)
------------------------------------------------------------
Recap: Immunize.org adds new PCV21 to “Ask the Experts: Pneumococcal” web section
Immunize.org updated all the questions and answers on its popular Ask the Experts: Pneumococcal ([link removed]) web page. The clinical content now reflects updated recommendations for PCV21 vaccine (Capvaxive, Merck) as an option for adults age 18 years or older who are recommended to receive a pneumococcal conjugate vaccine. Hyperlinks were also updated as needed.
[link removed]
Immunize.org’s Ask the Experts ([link removed]) main page leads you to 30 web pages on various topics with more than 1,300 common or challenging questions and answers about vaccines and their administration. Immunize.org’s team of experts includes Kelly L. Moore, MD, MPH (team lead); Carolyn B. Bridges, MD, FACP; Iyabode Beysolow, MD, MPH; and Jane R. Zucker, MD, MPH.
Related Link
* Immunize.org: Ask the Experts ([link removed]) main page with more than 1,300 questions and answers
Back to top (#Top)
------------------------------------------------------------
Recap: Immunize.org adds new vaccines to popular resource “Before You Vaccinate Adults, Consider Their ‘H-A-L-O’!”
Immunize.org recently updated its resource for healthcare professionals titled Before You Vaccinate Adults, Consider Their “H-A-L-O” ([link removed]) !
H-A-L-O refers to four factors:
* Health condition
* Age
* Lifestyle
* Occupation
The document now includes mpox vaccine and updated polio (IPV) vaccination recommendations for previously unvaccinated adults. The RSV vaccine section was revised to match the June 2024 ACIP recommendations for routine vaccination of adults age 75 years and older, and risk-based vaccination of adults age 60 through 74 years.
[link removed]
Related Links
* Immunize.org: Clinic Tools: Vaccine Recommendations ([link removed]) web page
* Immunize.org: Clinical Resources A–Z ([link removed]) main page, where you can filter by topic, vaccine, language, or other criteria
Back to top (#Top)
------------------------------------------------------------
Recap: Immunize.org updates “Vaccines with Diluents: How to Use Them” resource
Immunize.org recently added Penbraya (MenABCWY, Pfizer) to its Vaccines with Diluents: How to Use Them ([link removed]) and updated the resource to specify the formulation of Pfizer-BioNTech COVID-19 vaccine that requires dilution.
[link removed]
Related Links
* Immunize.org: Clinical Resources: Storage & Handling ([link removed]) main page
* Immunize.org: Clinical Resources A–Z ([link removed]) main page, where you can filter by topic, vaccine, language, or other criteria
Back to top (#Top)
------------------------------------------------------------
Featured Resources
------------------------------------------------------------
Champions for Vaccine Education, Equity, and Progress releases “Stay Updated” campaign to explain the importance of receiving updated COVID-19 and influenza vaccines
Champions for Vaccine Education, Equity, and Progress ([link removed]) (CVEEP), led by the Alliance for Aging Research, HealthyWomen, and the National Caucus and Center on Black Aging, released its Stay Updated ([link removed]) campaign. This promotion highlights the importance of receiving updated COVID-19 and influenza vaccines this season. This campaign offers fact sheets, an informational poster, a glossary of virology terms, and an information sheet on milestones in COVID-19 vaccination.
[link removed]
Visit CVEEP's Stay Updated campaign ([link removed]) to learn more about the need for updated vaccines and access resources to encourage your community to stay protected.
Back to top (#Top)
------------------------------------------------------------
Explore the www.Give2MenACWY.org website to increase coverage for the meningococcal ACWY booster and other adolescent vaccinations
Immunize.org's www.Give2MenACWY.org ([link removed]) website promotes the importance of adolescent vaccination, including the recommended MenACWY vaccine booster dose at age 16. Many teens are behind on vaccines because of the pandemic, so vaccine outreach is more important than ever.
Materials on this colorful website for healthcare professionals incorporate the 2020 ACIP meningococcal vaccine recommendations ([link removed]) and coverage statistics from CDC’s National Immunization Survey–Teen (NIS–Teen). One particularly popular resource on the site is the Algorithm for MenACWY Immunization in Adolescents 11 through 18 Years of Age ([link removed]) .
[link removed]
The website is divided into five easy-to-access sections:
* Vaccinate Teens ([link removed]) – Teen vaccination schedules and tips for improving vaccination rates
* Give 2 Doses ([link removed]) – Tools to help improve second dose coverage of MenACWY vaccine
* 16-Year-Old Visit ([link removed]) – Resources to help providers and patients remember the important vaccines recommended for 16-year-olds
* Tools for Providers ([link removed]) – Tools to explain meningococcal ACWY vaccine recommendations and improve coverage for all adolescent vaccines
* Resources ([link removed]) – Links to print materials ([link removed]) , organizations ([link removed]) involved in adolescent vaccination, personal stories ([link removed]) about the importance of vaccination, and other resources ([link removed]) of interest
The site also categorizes materials ([link removed]) according to whether they are primarily of interest to providers, to adolescents, or to parents.
Visit Give2MenACWY.org ([link removed]) and enjoy browsing (and deploying) its bountiful resources.
Related Links
* Give2MenACWY.org ([link removed]) website
* Algorithm for MenACWY Immunization in Adolescents 11–18 Years of Age ([link removed])
* MenACWY: You're Not Done If You Give Just One: Give 2 Doses to Strengthen Protection ([link removed])
* Recommending MenACWY: What to Say and How to Say It ([link removed])
* Top 10 Ways to Improve Adolescent Immunization Rates ([link removed])
* Developing an Immunization Culture in Your Office ([link removed])
* Know Your Rates: Measuring Immunization Success in Your Practice ([link removed])
* You're 16: We Recommend These Vaccines for You ([link removed])
* Dear Colleague Letter: 16-Year-Old Patients: Make Sure They Receive Their Annual Well Visit and Vaccinations ([link removed]) – signed by six medical societies
* Ask the Experts: Meningococcal ACWY ([link removed])
* CDC: ACIP Meningococcal Vaccine Recommendations ([link removed])
* CDC: Vaccination Coverage Among Adolescents Aged 13–17 Years—National Immunization Survey–Teen, United States, 2023 ([link removed])
Back to top (#Top)
------------------------------------------------------------
Notable Publications
------------------------------------------------------------
“Back to School Means Updating Childhood Vaccines” published in Clinical Advisor
In its August 23 issue, Clinical Advisor published Back to School Means Updating Childhood Vaccines ([link removed]) . This article was written by Immunize.org’s Mary Beth Koslap-Petraco, DNP, FAANP. The introduction paragraph appears below.
The lazy, crazy days of summer are drawing to a close and it is time to start thinking about back to school and all that entails to prepare students to optimize their health. Vaccines can be number one on the list. We need to take a serious look at how the number of children who receive all necessary vaccines for school has dropped since the COVID-19 pandemic began its devastating march around the world. The immunization rates are even lower in children who are eligible for the Vaccines for Children (VFC) program. This federal program provides no-cost vaccines to children who are uninsured or are Medicaid eligible. In some states VFC also covers children whose insurance does not cover vaccines. It is time to review what vaccines are indicated to keep all students healthy and practice some infection prevention.
Back to top (#Top)
------------------------------------------------------------
Upcoming Events
------------------------------------------------------------
Virtual: Watch September 12–13 National Vaccine Advisory Committee meeting addressing hepatitis B, tuberculosis, and HIV vaccines
National Vaccine Advisory Committee (NVAC) meetings ([link removed]) are held three times each year to address pressing topics affecting the vaccine enterprise. The September 12–13 NVAC agenda ([link removed]) topics include implementation of the universal hepatitis B vaccine recommendations for adults age 19–59 years, new approaches for tuberculosis vaccine innovation, and research to inform future HIV vaccine development. NVAC will also host panels on vaccine equity, provider payment, and planning for the development of the next national vaccine strategy.
The hepatitis B panel will include Immunize.org CEO, Kelly L. Moore, MD, MPH, discussing challenges and opportunities to increase HepB coverage in adults.
NVAC meetings are open to the public and can be viewed virtually. Preregistration ([link removed]) is required for both public attendance and comment.
View the September 12–13 NVAC Meeting ([link removed]) web page for more information.
Back to top (#Top)
------------------------------------------------------------
For more upcoming events, visit our Calendar of Events ([link removed]) .
Editorial Information
Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Grabenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Kayla Ohlde
About IZ Express
Immunize.org welcomes redistribution of this issue of IZ Express or selected articles.
When you do so, please add a note that Immunize.org is the source of the material and provide a link to this issue ([link removed]) .
IZ Express is supported in part by Grant No. 1NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer ([link removed])
ISSN: 2771-8085
This email was sent to [email protected] (mailto:[email protected])
why did I get this? ([link removed]) unsubscribe from this list ([link removed]) update subscription preferences ([link removed])
Immunize.org . 2136 Ford Parkway . Suite 5011 . Saint Paul, MN 55116 . USA
Message Analysis
- Sender: Immunization Action Coalition
- Political Party: n/a
- Country: United States
- State/Locality: n/a
- Office: n/a
-
Email Providers:
- MailChimp